Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129363 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety of Twice Daily Oral Carvedilol
A Phase 3 study of Congestive Heart Failure, sponsored by Shaddy, Robert, M.D..
- Completed
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 17
- Study locations
NCT00129363 is a Phase 3 study of Congestive Heart Failure that has completed, run by Shaddy, Robert, M.D.. The registered enrollment target is 75 participants, below the 329-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (77% lower). The trial reports 17 study locations across 13 states.
The verdict
NCT00129363, a Phase 3 study of Congestive Heart Failure, has completed, sponsored by Shaddy, Robert, M.D..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 17
- Study locations
Study Summary
The objective of this study is to evaluate the long-term safety of carvedilol in pediatric patients with chronic heart failure, who completed the Pediatric Carvedilol Study 321. Carvedilol will be provided as open-label therapy for a period of at least 6 months (or until termination of the study) by SmithKline Beecham Corporation d/b/a GlaxoSmithKline (GSK) or the University Sponsor.
Conditions Studied
Interventions
- DRUG Carvedilol
Study Locations (17)
California
- Mattel Children's Hospital at UCLA - Los Angeles
- Children's Hospital Los Angeles - Los Angeles
- Stanford University - Palo Alto
Michigan
- C.S. Mott Children's Hospital - Ann Arbor
- Children's Hospital of Michigan - Detroit
Texas
- UT Southwestern Medical Center - Dallas
- Texas Children's Hospital - Houston
Colorado
- University of Colorado - Denver
Florida
- University of Miami - Miami
Illinois
- Children's Memorial Hospital - Chicago
Massachusetts
- Children's Hospital, Boston - Boston
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2002-01 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129363
The ClinicalTrials.gov registry entry for NCT00129363 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 329-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (77% lower). The listed sponsor is Shaddy, Robert, M.D., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Carvedilol is the first listed.
NCT00129363 reports 17 study locations spanning 13 distinct geographic areas - top geographies include California, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT00129363 about?
NCT00129363 is a clinical study titled "Study to Evaluate the Safety of Twice Daily Oral Carvedilol". The objective of this study is to evaluate the long-term safety of carvedilol in pediatric patients with chronic heart failure, who completed the Pediatric Carvedilol Study 321. Carvedilol will be provided as open-label therapy for a period of at least 6 months (or until termination of the study) by...
What is the current status of trial NCT00129363?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2002-01. Estimated completion is 2006-01.
What conditions does trial NCT00129363 study?
This clinical trial studies the following conditions: Congestive Heart Failure.
What interventions are being tested in trial NCT00129363?
The interventions under investigation include: Carvedilol (DRUG).
Who is sponsoring clinical trial NCT00129363?
This trial is sponsored by Shaddy, Robert, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00129363 being conducted?
This trial has 17 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congestive Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
COMPLETED · Phase 3
-
DILIPO (DILutIonal HyPOnatremia)
COMPLETED · Phase 3
-
Palliative Care for People With HF
RECRUITING
-
Circulating Markers for Ischemic Heart Disease
RECRUITING
-
Stress and Congestive Heart Failure
RECRUITING · NA
-
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.